Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study

Hoang Van Minh, Nguyen Thi Tuyet My, Mark Jit, Hoang Van Minh, Nguyen Thi Tuyet My, Mark Jit

Abstract

Background: Cervical cancer is currently the leading cause of cancer mortality among women in South Vietnam and the second leading cause of cancer mortality in North Vietnam. Human papillomavirus (HPV) vaccination has the potential to substantially decrease this burden. The World Health Organization (WHO) recommends that a cost-effectiveness analysis of HPV vaccination is conducted before nationwide introduction.

Methods: The Papillomavirus Rapid Interface for Modeling and Economics (PRIME) model was used to evaluate the cost-effectiveness of HPV vaccine introduction. A costing study based on expert panel discussions, interviews and hospital case note reviews was conducted to explore the cost of cervical cancer care.

Results: The cost of cervical cancer treatment ranged from US$368 - 11400 depending on the type of hospital and treatment involved. Under Gavi-negotiated prices of US$4.55, HPV vaccination is likely to be very cost-effective with an incremental cost per disability-adjusted life year (DALY) averted in the range US$780 - 1120. However, under list prices for Cervarix and Gardasil in Vietnam, the incremental cost per DALY averted for HPV vaccination can exceed US$8000.

Conclusion: HPV vaccine introduction appears to be economically attractive only if Vietnam is able to procure the vaccine at Gavi prices. This highlights the importance of initiating a nationwide vaccination programme while such prices are still available.

Keywords: Cervical cancer; Cost-effectiveness analysis; Human papillomavirus; PRIME; Vietnam.

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Du Cancer. 2010;127(12):2893–917. doi: 10.1002/ijc.25516.
    1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86. doi: 10.1093/annonc/mdr015.
    1. Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012 [Internet]. 2016 [cited Accessed 15 May 2016]. Available from: .
    1. Subramanian S, Trogdon J, Ekwueme DU, Gardner JG, Whitmire JT, Rao C. Cost of cervical cancer treatment: implications for providing coverage to low-income women under the Medicaid expansion for cancer care. Womens Health Issues. 2010;20(6):400–5. doi: 10.1016/j.whi.2010.07.002.
    1. Novaes HM, Itria A, Silva GA, Sartori AM, Rama CH, Soarez PC. Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil. Clinics (Sao Paulo, Brazil) 2015;70(4):289–95. doi: 10.6061/clinics/2015(04)12.
    1. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine. 2008;26(49):6244–57. doi: 10.1016/j.vaccine.2008.07.056.
    1. Ezat WP, Aljunid S. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev. 2010;11(1):79–90.
    1. Rey-Ares L, Ciapponi A, Pichon-Riviere A. Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis. Arch Argent Pediatr. 2012;110(6):483–9.
    1. Ezat SW, Aljunid S. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev. 2010;11(4):943–51.
    1. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884. doi: 10.1136/bmj.b3884.
    1. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea MK, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007;25(33):6257–70. doi: 10.1016/j.vaccine.2007.05.058.
    1. Kahn JA, Bernstein DI. Human papillomavirus vaccines and adolescents. Curr Opin Obstet Gynecol. 2005;17(5):476–82. doi: 10.1097/01.gco.0000179505.14623.ef.
    1. Anh PT, Parkin DM, Hanh NT, Duc NB. Cancer in the population of Hanoi, Vietnam, 1988-1990. Br J Cancer. 1993;68(6):1236–42. doi: 10.1038/bjc.1993.511.
    1. Nguyen QM, Nguyen HC, Parkin DM. Cancer incidence in Ho Chi Minh City, Viet Nam, 1995-1996. Int J Cancer. 1998;76(4):472–9. doi: 10.1002/(SICI)1097-0215(19980518)76:4<472::AID-IJC5>;2-O.
    1. Domingo EJ, Noviani R, Noor MR, Ngelangel CA, Limpaphayom KK, Thuan TV, et al. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine. 2008;26(Suppl 12):M71–9. doi: 10.1016/j.vaccine.2008.05.039.
    1. Countries eligible for support 2016 [Internet]. 2016 [cited Accessed 20 May 2016]. Available from: .
    1. Vaccine price commitments from manufacturers [Internet]. 2015 [cited Accessed 28 May 2016]. Available from: .
    1. Levin CE, Van Minh H, Odaga J, Rout SS, Ngoc DN, Menezes L, et al. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bull World Health Organ. 2013;91(8):585–92. doi: 10.2471/BLT.12.113837.
    1. Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine. 2008;26(32):4015–24. doi: 10.1016/j.vaccine.2008.05.038.
    1. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406–14. doi: 10.1016/S2214-109X(14)70237-2.
    1. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effective analysis. Geneva: World Health Organization; 2003.
    1. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89:821–30B. doi: 10.2471/BLT.11.089862.
    1. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health. 2009;9:29. doi: 10.1186/1471-2458-9-29.
    1. Le P, Griffiths UK, Anh DD, Franzini L, Chan W, Swint JM. Cost-effectiveness of Haemophilus influenzae type b vaccine in Vietnam. Vaccine. 2015;33(36):4639–46. doi: 10.1016/j.vaccine.2015.05.050.
    1. Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. PharmacoEconomics. 2014;32(6):525–31. doi: 10.1007/s40273-014-0162-x.
    1. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bulletin of the World Health Organization. 2015;93(2):118–24. doi: 10.2471/BLT.14.138206.
    1. Jit M, Dang TT, Friberg I, Hoang VM, Pham Huy TK, Walker N, et al. Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national expanded programme on immunization. Vaccine. 2015;33(Suppl 1):A233–9. doi: 10.1016/j.vaccine.2014.12.017.
    1. Bui NC, Kim GB, Nguyen TH, Nguyen LH, Van Hoang M. Willingness to pay for a quality adjusted life year in Bavi district, Hanoi 2014. Vietnam J Public Health. 2014;2(2):42.
    1. Poulos C, Yang JC, Levin C, Van Minh H, Giang KB, Nguyen D. Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Social Sci Med (1982) 2011;73(2):226–34. doi: 10.1016/j.socscimed.2011.05.029.
    1. Herlihy N, Hutubessy R, Jit M. Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries. Health Affairs (Project Hope) 2016;35(2):227–34. doi: 10.1377/hlthaff.2015.1411.
    1. Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31(37):3786–804. doi: 10.1016/j.vaccine.2013.06.060.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever